Vanda Pharmaceuticals Inc. VNDA today announced its exclusive license agreement with Megapharm Ltd.pharmaceutical and medical nutrition marketing companies, for the commercialization of Fanapt™ in Israel.
Under the terms of the agreement, Megapharm will seek regulatory approval for Fanapt™ in Israel. Vanda will supply Megapharm with Fanapt™ drug product for packaging and sale and Megapharm's CNS specialty sales force will promote Fanapt™ to psychiatrists in Israel. The application for regulatory approval of Fanapt™ in Israel was filed in May 2011.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in